

# AvMed

## PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST\*

**Directions:** The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; **fax to 1-305-671-0200.** No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

### SQ tocilizumab products

**Drug Requested:** select one drug below (**Pharmacy**)

<input type="checkbox"/> Actemra <sup>®</sup> SQ (tocilizumab)	<input type="checkbox"/> Tyenne <sup>®</sup> SQ (tocilizumab-aazg)
--	--

**MEMBER & PRESCRIBER INFORMATION:** Authorization may be delayed if incomplete.

Member Name: \_\_\_\_\_  
Member AvMed #: \_\_\_\_\_ Date of Birth: \_\_\_\_\_  
Prescriber Name: \_\_\_\_\_  
Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_  
Office Contact Name: \_\_\_\_\_  
Phone Number: \_\_\_\_\_ Fax Number: \_\_\_\_\_  
NPI #: \_\_\_\_\_

**DRUG INFORMATION:** Authorization may be delayed if incomplete.

Drug Name/Form/Strength: \_\_\_\_\_  
Dosing Schedule: \_\_\_\_\_ Length of Therapy: \_\_\_\_\_  
Diagnosis: \_\_\_\_\_ ICD Code, if applicable: \_\_\_\_\_  
Weight (if applicable): \_\_\_\_\_ Date weight obtained: \_\_\_\_\_

**NOTE:** The Health Plan considers the use of concomitant therapy with more than one biologic immunomodulator (e.g., Dupixent, Entyvio, Humira, Rinvoq, Stelara) prescribed for the same or different indications to be experimental and investigational. Safety and efficacy of these combinations has **NOT** been established and will **NOT** be permitted.

- Will the member be discontinuing a previously prescribed biologic if approved for requested medication?  
 Yes **OR**  No
- If yes, please list the medication that will be discontinued and the medication that will be initiated upon approval along with the corresponding effective date.

Medication to be discontinued: \_\_\_\_\_ Effective date: \_\_\_\_\_

Medication to be initiated: \_\_\_\_\_ Effective date: \_\_\_\_\_

(Continued on next page)

**CLINICAL CRITERIA:** Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

**Diagnosis: Moderate-to-Severe Rheumatoid Arthritis**

**Dosing: SubQ:** <100 kg – 162 mg once every other week; >100 kg – 162 mg once every week

- Member has a diagnosis of moderate-to-severe **rheumatoid arthritis**
- Prescribed by or in consultation with a **Rheumatologist**
- Member has tried and failed at least **ONE** of the following **DMARD** therapies for at least **three (3) months**
  - hydroxychloroquine
  - leflunomide
  - methotrexate
  - sulfasalazine
- Member meets **ONE** of the following:
  - Member tried and failed, has a contraindication, or intolerance to **ONE** of the following:
    - ONE** preferred adalimumab product [**NOTE: COMM/FAMIS preferreds = Humira/Cyltezo/Yuflyma** - Humira NDC's starting with 83457 are not approved, NDC's starting with 00074 (MFG: Abbvie) are preferred; **SG/IP/HIX preferreds = Simlandi or adalimumab-adbm**]
    - Other Tumor Necrosis Factor (TNF) blocker medication approved for treatment of Moderate-to-Severe Rheumatoid Arthritis: \_\_\_\_\_
  - Member has been established on requested medication for at least 90 days **AND** prescription claims history indicates **at least a 90-day supply of requested medication was dispensed within the past 130 days** (verified by chart notes or pharmacy paid claims)

**Diagnosis: Juvenile Idiopathic Arthritis**

**Dosing: SubQ:**

- **PJIA:** <30 kg – 162 mg once every 3 weeks; ≥30 kg – 162 mg once every 2 weeks
- **SJIA:** <30 kg – 162 mg once every 2 weeks; ≥30 kg – 162 mg once every week

- Member is ≥ 2 years of age and has a diagnosis of **ONE** of the following:
  - Active polyarticular juvenile idiopathic arthritis (PJIA)**
  - Active systemic juvenile idiopathic arthritis**
- Prescribed by or in consultation with a **Rheumatologist**

(Continued on next page)

- Member has tried and failed at least **ONE** of the following **DMARD** therapies for at least **three (3) months**
  - cyclosporine
  - hydroxychloroquine
  - leflunomide
  - methotrexate
  - Non-steroidal anti-inflammatory drugs (NSAIDs)
  - oral corticosteroids
  - sulfasalazine
  - tacrolimus
- For members with a diagnosis of **PJIA only**, member meets **ONE** of the following:
  - Member tried and failed, has a contraindication, or intolerance to **ONE** of the following:
    - ONE** preferred adalimumab product [**NOTE: COMM/FAMIS preferreds = Humira/Cyltezo/Yuflyma** - Humira NDC's starting with 83457 are not approved, NDC's starting with 00074 (MFG: Abbvie) are preferred; **SG/IP/HIX preferreds = Simlandi or adalimumab-adbm**]
    - Other Tumor Necrosis Factor (TNF) blocker medication approved for treatment of Active Polyarticular Juvenile Idiopathic Arthritis: \_\_\_\_\_
  - Member has been established on requested medication for at least 90 days **AND** prescription claims history indicates **at least a 90-day supply of requested medication was dispensed within the past 130 days** (verified by chart notes or pharmacy paid claims)

Medication being provided by Specialty Pharmacy – Proprium Rx

***\*\*Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.\*\****

***\*Previous therapies will be verified through pharmacy paid claims or submitted chart notes.\****